Alivus Life Q1 FY27 results (Apr–Jun 2026) and concall

Healthcare · Concall AI · Call held 31 Jul 2026

Company page: Alivus Life share price, financials & guidance record

Alivus Life Sciences reported a strong Q1 FY27 with 6.4% YoY revenue growth to INR640 crores, primarily driven by a robust 26.5% growth in its non-GPL business, which offset a significant decline in the GPL segment. Profitability saw substantial improvement with gross margins at 60.2% and EBITDA margins at 36.6%, attributed to product mix, new launches, and operational efficiencies. The company maintains a debt-free status and is progressing with its capex plans, despite a slight delay in the Solapur facility.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q1 FY27: revenue up 6.3%, net profit up 31.1% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue	507	642	650	602	588 +16%	673 +5%	689 +6%	640 +6%
Expenses	373	452	451	430	409	442	475	429
EBITDA	134	190	198	172	179 +34%	231 +22%	215 +9%	212 +23%
Margin	27%	30%	31%	29%	30%	34%	31%	33%
Other income	9	10	10	9	15	-12	23	22
Interest	0	0	1	1	1	1	1	1
Depreciation	15	15	16	17	18	20	20	21
Profit before tax	127	185	191	163	174 +37%	198 +7%	216 +13%	212 +30%
Tax rate	25%	26%	26%	25%	25%	24%	25%	25%
Net profit	95	137	142	122	130 +37%	150 +9%	163 +15%	160 +31%
EPS	7.78	11.18	11.58	9.91	10.60	12.25	13.25	13.04

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Healthcare earnings calls